Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 537 shares of the medical research company’s stock after selling 115 shares during the quarter. Roman Butler Fullerton & Co.’s holdings in Thermo Fisher Scientific were worth $294,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Coppell Advisory Solutions LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $33,000. Live Oak Investment Partners purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $36,000. Tyler Stone Wealth Management purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $37,000. Raleigh Capital Management Inc. boosted its holdings in Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 27 shares during the period. Finally, Cedar Mountain Advisors LLC boosted its holdings in Thermo Fisher Scientific by 107.0% during the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 46 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 1.0 %

TMO opened at $541.78 on Friday. The firm has a market cap of $206.80 billion, a price-to-earnings ratio of 35.07, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The business’s 50 day moving average is $571.39 and its two-hundred day moving average is $527.11. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the business earned $5.40 earnings per share. The business’s revenue was down 4.9% on a year-over-year basis. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Analysts Set New Price Targets

Several brokerages have recently issued reports on TMO. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.